Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update
Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer
VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update
Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China
VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer
VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update
